OnKure Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 10, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 10, 2025
OKUR$3.19+11.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except par value and share data)
| December 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $110,761 | $29,876 |
| Prepaid expenses and other current assets | 2,242 | 3,890 |
| Total current assets | 113,003 | 33,766 |
| Property and equipment, net | 1,025 | 1,432 |
| Operating lease right-of-use asset | 770 | 478 |
| Other assets | 109 | 58 |
| Total assets | $114,907 | $35,734 |
| LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Current liabilities: | ||
| Accounts payable | $2,968 | $3,417 |
| Accrued expenses | 7,026 | 3,660 |
| Operating lease liabilities, current portion | 536 | 208 |
| Total current liabilities | 10,530 | 7,285 |
| Long-term operating lease liabilities | 549 | 466 |
| Total liabilities | 11,079 | 7,751 |
| Commitments and contingencies (Note 14) | ||
| Convertible preferred stock, Series C, $0.0001 par value; no shares and 7,404,919 shares authorized; no shares and 6,840,620 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively; liquidation preference of $195,823 as of December 31, 2023 | — | 129,825 |
| Stockholders’ equity (deficit): | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding at December 31, 2024 | — | — |
| Common stock, Class A, $0.0001 par value; 200,000,000 and 943,840 shares authorized; 12,660,590 and 313,747 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | 1 | — |
| Common stock, Class B, $0.0001 par value; 10,000,000 and 226,285 shares authorized; 686,527 and no shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | — | — |
| Additional paid-in capital | 258,551 | 209 |
| Accumulated deficit | (154,724) | (102,051) |
| Total stockholders’ equity (deficit) | 103,828 | (101,842) |
| Total liabilities, convertible preferred stock, and stockholders’ equity (deficit) | $114,907 | $35,734 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.